CJC-1295 With DAC

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic peptide comprising 30 amino acids, structurally similar to the endogenous growth hormone-releasing hormone (GHRH). The key modification is the incorporation of a maleimidopropionic acid (MPA) group, which allows for covalent conjugation with serum albumin. This albumin binding significantly extends its half-life in circulation compared to unmodified GHRH or its shorter analog, CJC-1295 without DAC. This prolonged presence enables a sustained stimulation of somatotroph cells in the anterior pituitary, promoting the pulsatile release of growth hormone. Research into CJC-1295 with DAC has focused on understanding the mechanisms of sustained GHRH receptor activation and its downstream effects on the somatotropic axis. Studies have explored its pharmacokinetic and pharmacodynamic properties, particularly the impact of the DAC modification on its in vivo stability and biological activity. The sustained action of CJC-1295 with DAC provides a valuable tool for investigating the long-term regulation of growth hormone secretion and its physiological implications. The peptide's molecular structure, C165H269N47O46S, and molecular weight of 3647.28 g/mol, underpin its specific interactions within biological systems. Its stability and extended half-life make it suitable for research requiring prolonged GHRH receptor engagement without frequent administration, facilitating studies on chronic regulatory processes within the endocrine system.